ZeaVaxx
Innovative plant-derived nanoparticle adjuvants enhancing vaccine effectiveness for optimal immune response in animals.
Innovative plant-derived nanoparticle adjuvants enhancing vaccine effectiveness for optimal immune response in animals.
ZeaVaxx is a biotechnology startup launched in 2017. The company specializes in animal vaccines and is known for its innovative plant-derived nanoparticle adjuvants. Their flagship product, Zea-11, has been designed to address unmet needs in the industry, offering a unique solution to enhance vaccine effectiveness. ZeaVaxx focuses on incorporating their plant-based adjuvants into vaccine formulations to help optimize immune responses in animals.
The startup recently secured a $50.00K Pre Seed Round investment on 01 June 2018, with the Purdue Ag-celerator participating as the primary investor. This funding round is a testament to the investor confidence in ZeaVaxx's technological innovation and potential impact within the animal vaccine market.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Pre Seed Round | $50.00K | 1 |
|
01 Jun 2018 |
No recent news or press coverage available for ZeaVaxx.
We care about your data, and we'd love to use cookies make your experience better.